SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 22,486 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50. Following the sale, the chairman owned 3,558,807 shares in the company, valued at $18,683,736.75. This represents a 0.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total transaction of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.

SOPHiA GENETICS Stock Performance

SOPH stock opened at $5.44 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The company has a 50 day moving average price of $5.13 and a 200 day moving average price of $4.97. SOPHiA GENETICS SA has a fifty-two week low of $2.92 and a fifty-two week high of $6.30. The stock has a market capitalization of $456.36 million, a PE ratio of -10.46 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently made changes to their positions in SOPH. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS in the third quarter valued at approximately $49,000. Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $49,000. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS in the 1st quarter worth $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS in the 4th quarter worth $54,000. Finally, XTX Topco Ltd bought a new position in SOPHiA GENETICS during the 4th quarter worth about $55,000. Institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

SOPH has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average target price of $7.50.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were mostly routine, pre-planned transactions tied to equity-award vesting and tax withholding, which suggests they may not signal a fundamental change in the business or management’s outlook.
• Neutral Sentiment: Multiple executives and directors, including Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, and others, reported sales in the same period, increasing investor focus on insider activity.
• Negative Sentiment: Even if planned, the cluster of insider share sales can create pressure on sentiment because it may be interpreted as reduced confidence or excess supply in the stock near term.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.